USA: Why DHS is Shutting Down CBD Infused Food Sales! It’s TOXIC!!

Spread the love

CBD-Infused Food Banned by Health Department at NYC Restaurant, Owner Says

Fat Cat Kitchen on 14th Street says DOH embargoed all its CBD-laced pastries by Serena Dai Feb 4, 2019,

A Gramercy Park neighborhood restaurant and bakery says that the Department of Health forced it to stop selling food with CBD, embargoing cookies and other pastries containing the legal compound derived from cannabis.

Fat Cat Kitchen’s co-owner C.J. Holm says that officials with the health department bagged up about $1,000 worth of cannabidiol (or CBD) edibles on Friday morning during a routine inspection, putting them in a zip-lock bag and marking them as “embargoed.” Holm is still in possession of the items.

DOH visited at least two other times in the recent past and did not mention the CBD products, even though Fat Cat Kitchen advertises the treats with a sign outside the restaurant, she alleges.

“I mean, this is crazy,” Holm says, alleging that at least two city staffers did not know what CBD was when she called for more information. “They couldn’t even intelligently explain to me exactly what the problem was when I spoke to them on the phone.”

CBD is a legal, non-psychoactive chemical compound that’s a relative of THC (tetrahydrocannabinol), the illegal compound in weed. In recent years, it has become increasingly popular to put into food products due to its purported (albeit sometimes questionable) therapeutic effects.

A Department of Health spokesperson did not immediately have a statement or further information. Eater will update when more details become available.

New York isn’t the only place facing this issue. Over the weekend, Maine’s health officials announced a ban on CBD edibles, saying that it’s not a federally approved food additive. But CBD itself – such as in a vape, as an oil, or in a lotion – is still okay to sell.

For more go to…

But here’s why DHS are doing this!!!






Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD). As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products. 1


Drug Contraindications

CBD oil may potentially interact in a negative way with anti-epilepsy drugs such as:

1. carbamazepine (Tegretol)

2. phenytoin (Dilantin)

3. phenobarbital (Luminal, Solfoton, Tedral)

4. primidone (anti-seizure) 2

Research published in the journal Cannabis and Cannabinoid Research shows that more than 40% of children with epilepsy who were given CBD orally had adverse events that included THC like symptoms, The research challenged the widely accepted premise that CBD is not intoxicating. 3

The most common side effects of CBD can include: 4

  • Sleepiness
  • Decreased appetite
  • Diarrhea
  • Change in liver function
  • Fatigue
  • Malaise
  • Asthenia (weakness or lack of energy)
  • Rash
  • Insomnia
  • Sleep disorder
  • Poor quality sleep
  • Infections
  • CBD also interacts with some other seizure medicines.
  • Nausea or vomiting
  • Dizziness
  • Anxiety or depression
  • Changes in appetite/weight





Conversion of CBD to THC

Researcher Kazuhito Watanabe, PhD and his team at Daiichi College of Pharmaceuticals, Japan discovered a disturbing problem with cannabidiol.

They found that CBD converts into THC, the same psychosis inducing substance found in weed. In addition, CBD converted into two other THC-like cannabinoids known as HHCs (hexahydroxycannabinols). All three produced high inducing symptoms in mice.

This research indicates that THC is not the only mind altering cannabinoid in hemp. It also suggests the possibility that a person can be exposed to brain altering, high inducing substances by simply consuming CBD.

Getting High on CBD?

Acidity is necessary for the conversion of CBD to THC and the two psychoactive HHCs. Researchers performed this conversion using artificial digestive juices. The change accelerated in the presence of some kind of sugar (or alcohol).

In people consuming CBD oil, this would parallel as acidity in the stomach. Since people commonly consume CBD oil in sugary lattes, candy, goodies, smoothies or alcoholic beverages, this situation mimics the reality of many people who use it.

Effects of THC Derived from CBD

To test the effects of these components, the researchers then injected mice with small quantities of the THC and HHCs converted from CBD. The researchers tested for the four most common symptoms of THC exposure including:

  • Catalepsy — loss of sensation or consciousness
  • Hypothermia — drop in body temperature
  • Prolonged sleep
  • Reduced pain perception
  • Mice injected with small amounts of THC and HHCs converted in artificial gastric juices from CBD tested positively for all 4 pot exposure symptoms.

Human Studies

Follow-up research in 2016 published in the journal Cannabis and Cannabinoid Research gives additional pause.

More than 40% of epileptic children orally administered CBD exhibited adverse events, with THC like symptoms the most common. In their conclusion, researchers challenged the accepted premise that CBD is not high-inducing.

Gastric fluid without enzymes converts CBD into the psychoactive components Δ9-THC and Δ8-THC, which suggests that the oral route of administration may increase the potential for psychomimetic adverse effects from CBD. (8)

Is CBD Oil Safe for Children?

The takeaway of existing research as of this writing seems to indicate extreme caution when it comes to ingestion of CBD oil especially by children.


From: Christine L. Miller, Ph.D., neuroscientist and author.

Yes, this is accurate information, beginning with an American Chemical Society paper (Adams, Wolff et al) that was published in 1940, confirmed by a Japanese group (Watanabe) in 2007, and more recently, by Merrick et al. (2016).  In terms of psychosis in adults, it is not such a bombshell, because the gastric-acid conversion of CBD to THC is only partial before it is absorbed into the blood stream, leaving enough CBD to counteract the psychosis-inducing effects (yes, CBD does block THC’s psychosis-inducing effects).  And for children with intractable seizure conditions, where it’s a race against time to prevent that potentially fatal seizure, the risk of psychosis from trace amounts of THC has to be weighed against the potentially fatal outcome of their seizures.  What it does mean for them, is that they should find a better route of administration of CBD than ingestion.

The most significant aspect of the CBD conversion to THC by gastric acid is what it explains about the variable impact of edibles, which are already rich in THC and losing the CBD to acid conversion means that you are losing the protective effect of CBD in terms of its psychosis-blocking effects.  This, coupled with the first pass metabolism of THC to 11-hydroxy THC (more potent psychotogen than THC itself) by the liver when THC is ingested (smoking THC does not result in first pass metabolism), can fully explain the erratic and sometimes horrific outcomes from edibles.


Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.

Metabolic and behavioural effects of, and interactions between Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are influenced by dose and administration route. Therefore we investigated, in Wistar rats, effects of pulmonary, oral and subcutaneous (sc.) THC, CBD and THC+CBD. Concentrations of THC, its metabolites 11-OH-THC and THC-COOH, and CBD in serum and brain were determined over 24h, locomotor activity (open field) and sensorimotor gating (prepulse inhibition, PPI) were also evaluated. In line with recent knowledge we expected metabolic and behavioural interactions between THC and CBD. While cannabinoid serum and brain levels rapidly peaked and diminished after pulmonary administration, sc. and oral administration produced long-lasting levels of cannabinoids with oral reaching the highest brain levels. Except pulmonary administration, CBD inhibited THC metabolism resulting in higher serum/brain levels of THC. Importantly, following sc. and oral CBD alone treatments, THC was also detected in serum and brain. S.c. cannabinoids caused hypolocomotion, oral treatments containing THC almost complete immobility. In contrast, oral CBD produced mild hyperlocomotion. CBD disrupted, and THC tended to disrupt PPI, however their combination did not. In conclusion, oral administration yielded the most pronounced behavioural effects which corresponded to the highest brain levels of cannabinoids. Even though CBD potently inhibited THC metabolism after oral and sc. administration, unexpectedly it had minimal impact on THC-induced behaviour. Of central importance was the novel finding that THC can be detected in serum and brain after administration of CBD alone which, if confirmed in humans and given the increasing medical use of CBD-only products, might have important legal and forensic ramifications.


Cannabidiol Does Not Convert to Δ9-Tetrahydrocannabinol in an In Vivo Animal Model.


INTRODUCTION: Cannabidiol (CBD) can convert to Δ9-tetrahydrocannabinol (THC) in vitro with prolonged exposure to simulated gastric fluid; however, in vitro conditions may not be representative of the in vivo gut environment. Using the minipig, we investigated whether enteral CBD converts to THC in vivo.

MATERIALS AND METHODS: Synthetic CBD (100 mg/mL) was administered orally in a sesame oil formulation twice daily to minipigs (N=3) in 15 mg/kg doses for 5 consecutive days. Blood samples were taken before and 1, 2, 4, and 6 h after morning doses on Days 1 and 5. Six hours after the final dose on Day 5, the animals were euthanized, and samples of gastrointestinal (GI) tract contents were obtained. Liquid chromatography with tandem mass spectrometry analysis determined CBD, THC, and 11-hydroxy-THC (11-OH-THC) concentrations. Lower limits of quantification: plasma CBD=1 ng/mL, plasma THC and 11-OH-THC=0.5 ng/mL, GI tract CBD=2 ng/mL, and GI tract THC and 11-OH-THC=1 ng/mL.

RESULTS: THC and 11-OH-THC were undetectable in all plasma samples. Maximum plasma concentrations (Cmax) of CBD were observed between 1 and 4 h on Days 1 and 5. CBD was present in plasma 6 h after administration on Days 1 (mean 33.6 ng/mL) and 5 (mean 98.8 ng/mL). Mean Cmax CBD values, 328 ng/mL (Day 1) and 259 ng/mL (Day 5), were within range of those achieved in clinical studies. Mean CBD exposure over 6 h was similar on Days 1 (921 h·ng/mL) and 5 (881 h·ng/mL). THC and 11-OH-THC were not detected in all GI tract samples. Mean CBD concentrations reached 84,500 ng/mL in the stomach and 43,900 ng/mL in the small intestine.

CONCLUSIONS: Findings of the present study show that orally dosed CBD, yielding clinically relevant plasma exposures, does not convert to THC in the minipig, a species predictive of human GI tract function.


A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans.

Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. Under acidic conditions, CBD can be transformed to delta9-tetrahydrocannabinol (THC) and other cannabinoids. It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of CBD to THC and delta8-THC in simulated gastric fluid (SGF) is a highly artificial approach that deviates significantly from physiological conditions in the stomach; therefore, SGF does not allow an extrapolation to in vivo conditions. Unsurprisingly, the conversion of oral CBD to THC and its metabolites has not been observed to occur in vivo, even after high doses of oral CBD. In addition, the typical spectrum of side effects of THC, or of the very similar synthetic cannabinoid nabilone, as listed in the official Summary of Product Characteristics (e.g., dizziness, euphoria/high, thinking abnormal/concentration difficulties, nausea, tachycardia) has not been observed after treatment with CBD in double-blind, randomized, controlled clinical trials. In conclusion, the conversion of CBD to THC in SGF seems to be an in vitro artifact.

1 See the 2016 warning letter section at:

2 Is CBD Oil Harmful or Healing? What No One is Telling You

3 Is CBD Oil Harmful or Healing? What No One is Telling You


Leave a Reply